On 2014 Aug 02, Christopher Southan commented:
For the record, since MeSH did not resolve AR79, the image from http://www.ncbi.nlm.nih.gov/pubmed/23872097 maps to https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53302375 that incudes a link to https://open.surechem.com/en/document/WO-2011089416-A1/
On 2014 Jul 30, Jim Woodgett commented:
The inhibitor used here, AR79, inhibits both GSK-3alpha and GSK-3beta with very similar potency (as do virtually all small molecule GSK-3 inhibitors developed to date). This is clearly shown in Table 1 of cited reference 11 (http://www.ncbi.nlm.nih.gov/pubmed/23872097) where the Ki against GSK-3beta is 3.2 nM vs an IC50 of 5.5nM for GSK-3alpha. Notably, the Astra-Zeneca authors are careful to term AR7 (and its related compounds) GSK-3 inhibitors.
On 2014 Jul 30, Jim Woodgett commented:
The inhibitor used here, AR79, inhibits both GSK-3alpha and GSK-3beta with very similar potency (as do virtually all small molecule GSK-3 inhibitors developed to date). This is clearly shown in Table 1 of cited reference 11 (http://www.ncbi.nlm.nih.gov/pubmed/23872097) where the Ki against GSK-3beta is 3.2 nM vs an IC50 of 5.5nM for GSK-3alpha. Notably, the Astra-Zeneca authors are careful to term AR7 (and its related compounds) GSK-3 inhibitors.
On 2014 Aug 02, Christopher Southan commented:
For the record, since MeSH did not resolve AR79, the image from http://www.ncbi.nlm.nih.gov/pubmed/23872097 maps to https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53302375 that incudes a link to https://open.surechem.com/en/document/WO-2011089416-A1/